Program
Indocyanine Green
Also written as “0.1 mg/kg ICG Dose”.
Its studies are mostly in Ischemia · Cholecystitis, Acute · Liver Failure, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cardiox | 10 open or running | phase 3since Sep 15, 2015 | Sep 15, 2015 | none ahead |
| Hamad Medical | 10 open or running | phase 4since Oct 30, 2020 | Oct 30, 2020 | none ahead |
| Research | 11 open or running | no phasesince Sep 1, 2026 | Sep 1, 2026 | Dec 1, 2026NCT07808957 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 15, 2015First study: phase 3 study in Liver FailureNew to CardioxCardiox · NCT02552901 · United States
- Oct 30, 2020Hamad Medical's first study: phase 4 study in Cholecystitis, AcuteNew to Hamad MedicalHamad Medical · NCT04624841 · 80 enrolled · Qatar
- Sep 1, 2026Research's first study: no phase study in Soft Tissue Filler ComplicationNew to ResearchResearch · NCT07808957 · 300 planned · Colombia
Ahead
- Dec 1, 2026Primary completion: no phase study in Soft Tissue Filler ComplicationResearch · NCT07808957
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07808957Soft Tissue Filler Complication · Colombia | – | Not yet recruiting | Research | Dec 1, 2026 | 300 |
| NCT04624841Cholecystitis, Acute · Qatar | 4 | UNKNOWN | Hamad Medical | Dec 31, 2021 | 80 |
| NCT02552901Liver Failure · United States | 3 | Withdrawn | Cardiox | May 2016 | 0 |
How it is read
Names in the registry
- “Indocyanine Green”, 2 entries
- “0.1 mg/kg ICG Dose”, 1 entry
Conditions, from the studies’ own filings
- Ischemia, 1 study
- Cholecystitis, Acute, 1 study
- Liver Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.